Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 2/20 | 0.91 |
| ▸ | CA5A | P35218 | 2/20 | 0.91 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.91 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.91 |
| ▸ | CA2 | P00918 | 2/20 | 0.91 |
| ▸ | CA12 | O43570 | 1/20 | 0.91 |
| ▸ | CA4 | P22748 | 1/20 | 0.91 |
| ▸ | CA6 | P23280 | 1/20 | 0.91 |
| ▸ | CA7 | P43166 | 1/20 | 0.91 |
| ▸ | CA9 | Q16790 | 1/20 | 0.91 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.82 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10228415 | 0.95 | CA3 (1.00) | CA3CA5ACA5BCA14CA2 | |
| SCHEMBL1274081 | 0.95 | CA3 (1.00) | CA3CA5ACA5BCA14CA2 | |
| SCHEMBL12936102 | 0.95 | CA3 (1.00) | CA3CA5ACA5BCA14CA2 | |
| SCHEMBL3142216 | 0.93 | CA3 (0.95) | CA3CA5ACA5BCA14CA2 | |
| SCHEMBL29982917 | 0.93 | MEN1 (1.00) | CA3CA5ACA5BCA14CA2 | |
| SCHEMBL27889238 | 0.91 | ALDH1A1 (1.00) | CA3CA5ACA5BCA14CA2 | |
| Trifluoroacetic Acid SCHEMBL1274516 | 0.90 | CA3 (0.88) | CA3CA5ACA5BCA14CA2 | |
| Trifluoroacetic Acid SCHEMBL1274119 | 0.90 | CA3 (0.88) | CA3CA5ACA5BCA14CA2 | |
| SCHEMBL19929280 | 0.89 | CA3 (0.72) | CA3CA5ACA5BCA14CA2 | |
| SCHEMBL18502181 | 0.88 | EPHX1 (0.79) | CA3CA5ACA5BCA14CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637492-B2 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo | GENE TOOLS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637492-B2 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo | GENE TOOLS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120035358-A1 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo | GENE TOOLS, LLC | 2012-02-09 | — | — | US | disclosed |
| US-7935816-B2 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo | GENE TOOLS, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090171075-A1 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo | GENE TOOLS, LLC | 2009-07-02 | — | — | US | disclosed |
| WO-2009055027-A2 | MOLECULAR TRANSPORTER COMPOSITIONS COMPRISING DENDRIMERIC OLIGOGUANIDINE WITH A TRI-FUNCTIONAL CORE THAT FACILITATE DELIVERY INTO CELLS IN VIVO | LI YONG-FU (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171075-A1 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo | SLC18A1, SLC75A1, SLC2A1 | CA3 2859/4885CA5A 798/4885CA5B 1174/4885 |
| US-20120035358-A1 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo | SLC29A2, SLC29A1, SLC2A9 | CA3 2869/4885CA5A 2048/4885CA5B 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.